1. Cost Effectiveness and Optimal Outcomes in HF

2. Content Overview

3. The Importance of Considering Cost Effectiveness

4. Epidemiology and Costs Associated With HF Care

5. Costs Accumulated During Hospitalization Eclipse All Other HF-Related Costs

6. Measuring Cost Effectiveness

7. Measuring Cost Effectiveness (cont)

8. New Therapies for HF

9. SOC vs Treatment With New Agents

10. Pure Heart Rate Reduction Through If Current Inhibition

11. Ivabradine SHIFT Study

12. Effect of Ivabradine on Outcomes

13. Hypothetical Cost Projections in 1 Year: 1-Million-Member Insurance Plan

14. SHIFT: Ivabradine Improves QoL in Patients With HF

15. Role of Heart Rate as a CV Risk Biomarker

16. PARADIGM-HF (Sacubitril/Valsartan) Results

17. Sacubitril/Valsartan Decreases Risk of Recurrent Hospitalizations for Worsening HF

18. Cost Effectiveness of Sacubitril/Valsartan

19. Cost Effectiveness of Sacubitril/ Valsartan (cont)

20. Challenging Conventional Wisdom…

21. Angioedema AEs During Randomized Treatment

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)